Mindray Medical's Overseas Revenue Exceeds China for the First Time — A Global Transformation Milestone for China's Top Device Maker

In the first quarter of 2026, Mindray witnessed its most pronounced structural shift since going public, as international business revenue exceeded domestic revenue for the first time at the quarterly level.

The Numbers

Mindray's 2025 annual report disclosed:

International business revenue: ¥17.65 billion, accounting for 53.03% of total revenue, with year-over-year growth of +7.40%

Chinese revenue: ¥15.63 billion, accounting for 46.97%

The 2026 Q1 quarterly report reinforced the trend:

International revenue: ¥4.449 billion, maintaining approximately 53% share, with year-over-year growth of +15.70% (+20% in USD terms)

Chinese revenue growth remained constrained

Regional Breakdown of International Growth

Europe: Year-over-year growth exceeding 25% in 2026 Q1, continuing a two-year high-growth trajectory

Developing countries: Year-over-year growth of +15% (+20% in USD terms)

North America: Stable growth with ongoing market penetration in mid-tier hospital segments

Chinese Market Dynamics

In China, Mindray's IVD (in-vitro diagnostics) market share has continued its steady upward trajectory:

Average market share across immunoassay, biochemistry, and coagulation segments rose from 12% (end of 2025) to 13% (Q1 2026)

The improvement reflects both organic product competitiveness gains and displacement of imported brands amid Chinese substitution policy tailwinds

Emerging Business Segments

Mindray's growth is increasingly driven by emerging business lines beyond its traditional "three pillars" (monitoring, IVD, ultrasound):

Emerging business revenue: ¥1.398 billion in Q1 2026, year-over-year growth +18.22%

Minimally invasive intervention: Year-over-year growth +25% — a segment where Mindray is establishing presence in endoscopy, surgical instruments, and vascular access

Animal medical: Double-digit growth, expanding the veterinary device market both domestically and internationally

Strategic Implications

The 53% international revenue share represents a watershed moment with several implications:

1. Growth Engine Switch: Mindray's incremental revenue growth is now primarily driven by international markets, particularly Europe and developing countries. Chinese growth — while stable — is increasingly constrained by volume-based procurement pressures and slower hospital capital expenditure cycles.

2. Competitive Positioning Transformation: Mindray is no longer simply "the leading Chinese device company" — it is increasingly perceived as a global competitor in the same competitive set as multinational peers (GE HealthCare, Philips, Siemens Healthineers) in mid-tier and emerging market hospital segments.

3. Risk Profile Diversification: International revenue diversification reduces Mindray's dependence on Chinese policy-driven market dynamics (procurement, pricing controls, hospital budget constraints), creating a more resilient revenue base.

4. Benchmark for the Industry: Mindray's transition establishes a template for other Chinese device companies. As the first major Chinese manufacturer to achieve international revenue dominance, Mindray demonstrates that the "from export to global" transition is achievable — validating the strategic direction that companies like Pushen Medical (endoscope), United Imaging (imaging), and others are pursuing.

Industry Implications

Mindray's milestone carries symbolic significance beyond the company itself. It demonstrates that Chinese medical device manufacturers can achieve genuine global market leadership — not merely cost-competitive export sales, but revenue-generating market penetration across developed and developing healthcare systems. For the broader ecosystem of Chinese device companies, this validates the strategy of investing in international regulatory credentials (FDA, CE, local registrations), building overseas commercial teams, and developing products that meet global clinical standards.